Healthcare provider profile · identity verified

Akiko Tsuzuki, MD

Internal Medicine · OAKLAND, CA · NPI 1679651459

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	419	143
Amlodipine Besylate	Amlodipine Besylate	233	85
Losartan Potassium	Losartan Potassium	143	52
Hydrochlorothiazide	Hydrochlorothiazide	114	43
Levothyroxine Sodium	Levothyroxine Sodium	112	32
Fluticasone Propionate	Fluticasone Propionate	104	36
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	100	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	91	33
Alendronate Sodium	Alendronate Sodium	83	30
Atenolol	Atenolol	73	26
Simvastatin	Simvastatin	65	21
Trazodone Hcl	Trazodone Hcl	65	23
Famotidine	Famotidine	64	26
Montelukast Sodium	Montelukast Sodium	64	21
Gabapentin	Gabapentin	58	24
Lisinopril	Lisinopril	55	23
Metoprolol Tartrate	Metoprolol Tartrate	53	19
Albuterol Sulfate Hfa	Albuterol Sulfate	52	24
Sertraline Hcl	Sertraline Hcl	51	16
Rosuvastatin Calcium	Rosuvastatin Calcium	49	19
Acyclovir	Acyclovir	48	16
Fluoxetine Hcl	Fluoxetine Hcl	48	14
Fluocinonide	Fluocinonide	40	25
Metformin Hcl Er	Metformin Hcl	38	19
Potassium Chloride	Potassium Chloride	38	16
Azelastine Hcl	Azelastine Hcl	35	18
Furosemide	Furosemide	35	14
Triamcinolone Acetonide	Triamcinolone Acetonide	33	19
Omeprazole	Omeprazole	32	16
Metoprolol Succinate	Metoprolol Succinate	31	12
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Alvesco	Ciclesonide	29	suppressed
Ibuprofen	Ibuprofen	29	11
Metformin Hcl	Metformin Hcl	29	suppressed
Lovastatin	Lovastatin	28	suppressed
Cefadroxil	Cefadroxil	26	22
Lorazepam	Lorazepam	25	13
Hydrocortisone	Hydrocortisone	24	14
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Nabumetone	Nabumetone	24	14
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Bupropion Xl	Bupropion Hcl	22	11
Prednisone	Prednisone	22	16
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	11
Meloxicam	Meloxicam	20	suppressed
Metronidazole	Metronidazole	20	15
Pregabalin	Pregabalin	20	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	19	19
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	19	16
Buspirone Hcl	Buspirone Hcl	18	suppressed
Colchicine	Colchicine	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Methadone Hcl	Methadone Hcl	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Torsemide	Torsemide	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Estradiol	Estradiol	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sumatriptan	Sumatriptan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error